Table 3.

White blood cell subsets in patients with metastatic colorectal cancer before and 2 months after treatment with cetuximab-based regimens.

	Before therapy			After therapy
	All patients	Responders	Non-responders	All patients	Responders	Non-responders
n	26	23	3	26	23	3
% CD16+ lymphocytes	16.25 ± 7.55	16.13 ± 7.85	17.24 ± 5.78	15.83 ± 9.69	14.97 ± 9.97	22.44 ± 2.27
% CD16+ lymphocytes in the overall white blood cells	2.43 ± 1.93	2.54 ± 2.02	1.56 ± 0.49	2.67 ± 2.84	2.71 ± 3.03	2.39 ± 0.41
% CD56+ lymphocytes	7.02 ± 6.67	6.88 ± 6.83	8.11 ± 6.36	7.60 ± 7.28	6.61 ± 6.15	15.21 ± 12.16
% CD56+ lymphocytes in the overall white blood cells	0.81 ± 0.87	0.82 ± 0.91	0.73 ± 0.50	1.00 ± 0.93	0.92 ± 0.86	1.60 ± 1.38
n	30	27	3	30	27	3
% CD16+CD56+ lymphocytes	4.30 ± 4.79	4.08 ± 4.83	6.23 ± 4.78	5.82 ± 6.44	5.21 ± 6.06	11.40 ± 8.47
% CD16+CD56+ lymphocytes in the overall white blood cells	0.54 ± 0.74	0.54 ± 0.78	0.56 ± 0.38	0.77 ± 0.87	0.72 ± 0.87	1.18 ± 0.95
n	38	35	3	38	35	3
% lymphocytes	15.57 ± 8.30	16.17 ± 8.36	8.58 ± 2.63	18.66 ± 12.81	19.50 ± 13.02	8.87 ± 0.75
% granulocytes	71.26 ± 11.66	70.52 ± 11.82	79.96 ± 4.38	68.2 ± 15.79	67.08 ± 15.93	81.71 ± 1.67
% granulocytes/% lymphocytes	6.48 ± 4.68	6.18 ± 4.70	9.95 ± 3.11	5.83 ± 4.35	5.53 ± 4.40	9.26 ± 0.90

The numbers represent mean ± SD.

The statistical significance of obtained data was evaluated by Wilcoxon signed rank test. No statistically significant differences were observed.